Patients vote with their feet for 'On demand' rabeprazole in the maintenance treatment phase of reflux oesophagitis.
Tan
V P Y
VP
Wong
B C Y
BC
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D017048:Health Care Costs; D006801:Humans; D010349:Patient Compliance; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064750:Rabeprazole